Last $3.72 USD
Change Today +0.04 / 1.09%
Volume 634.6K
PSTI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
Tel Aviv
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Snapshot

Open
$3.68
Previous Close
$3.68
Day High
$3.74
Day Low
$3.47
52 Week High
03/6/14 - $4.36
52 Week Low
12/29/14 - $2.32
Market Cap
261.3M
Average Volume 10 Days
821.6K
EPS TTM
$-0.43
Shares Outstanding
70.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PLURISTEM THERAPEUTICS INC (PSTI)

pluristem therapeutics inc (PSTI) Related Businessweek News

No Related Businessweek News Found

pluristem therapeutics inc (PSTI) Details

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented PLacental eXpanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company’s PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women’s health diseases; and PLX-RAD cells used for acute radiation syndrome treatment of animals, as well as products in pre-clinical trial for the treatment of pre-eclampsia and rotator-cuff repair. The company is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

160 Employees
Last Reported Date: 09/11/14
Founded in 2001

pluristem therapeutics inc (PSTI) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $503.7K
President and Chief Operating Officer
Total Annual Compensation: $270.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $129.9K
Compensation as of Fiscal Year 2014.

pluristem therapeutics inc (PSTI) Key Developments

Pluristem Therapeutics Inc. Announces Study Results of PLacental eXpanded (PLX) Cells

Pluristem Therapeutics Inc. announced that a study of PLacental eXpanded (PLX) cells was accepted for publication in the February, 2015 issue of Biochimica et Biophysica Acta [2]Molecular Cell Research. The study results show that PLX cells protect PC12 cells - an established model of various nerve cells including dopaminergic neurons from death after oxygen and glucose deprivation. The protective effects of PLX cells were strongly correlated with the secretion of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF), which are known to have neuroprotective effects in humans with injuries to the nervous system that can occur after events such as a stroke.

Pluristem and Hadassah Medical Center Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes

Pluristem Therapeutics Inc. announced that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem. The medical center's Department of Bone Marrow Transplantation and Cancer Immunotherapy, headed by Professor Reuven Or, will use preclinical models to assess the potential efficacy of PLX-RAD cells for treatment and prevention of hematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. PLX-RAD cells are Pluristem's second cell therapy product candidate.

Pluristem Therapeutics, Inc. Presents at Israel's 7th Annual Corporate Finance Conference, Nov-11-2014

Pluristem Therapeutics, Inc. Presents at Israel's 7th Annual Corporate Finance Conference, Nov-11-2014 . Venue: Leonardo City Tower, RamatGan, Israel. Speakers: Yaky Yanay, President and Chief Operating Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:US $3.72 USD +0.04

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.34 USD -0.04
Athersys Inc $2.09 USD -0.13
NeoStem Inc $3.54 USD -0.10
Ocata Therapeutics Inc $6.18 USD -0.05
SurModics Inc $22.92 USD +0.64
View Industry Companies
 

Industry Analysis

PSTI

Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 678.5x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 566.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit www.pluristem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.